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ABSTRACT
Background and Objectives: Hyperacute rejection (HAR) is a major obstacle to successful xenotransplantation of vascu-
larized organs. This study was conducted to observe the effect of hemolysis of perfused human whole blood on pig heart func-
tion, and determine the major risk factors for preservation of xenoperfused cardiac function using ex-vivo pig to human xe-
nogeneic cardiac perfusion model. Materials and Methods: Harvested pig hearts were perfused with normal human whole 
blood (group 1), two different types of pre-treated human whole blood (group 2: immunoglobulins were depleted by plasma-
pheresis, group 3: pre-treated with plasmapheresis, GAS914, cobra venom factor (CVF) and steroid), and normal porcine wh-
ole blood as control (group 4) for 3 hours. Results: Duration of heart beat was significantly prolonged in group 2 and group 3. 
Histological examination showed widespread HAR features but was gradually delayed in groups 2 and 3 compared to group 1. 
The absolute levels of serum creatine kinase-MB and Troponin I increased gradually, and was lower in group 3. Serum hemo-
globin levels were rapidly increased in groups 3 and 4, compared to group 1. Extracellular potassium level increased sharply from 
the beginning of blood perfusion in groups 1, 2 and 3, compared to group 4. Conclusion: Pretreatment of human whole blood, 
including immunoglobulin depletion, CVF and steroid reduced and delayed the destruction of pig myocardium by HAR. 
However, the increased extracellular potassium levels in groups 1, 2 and 3 reflected that these treatments could not prohibit 
myocardial injury by HAR. (Korean Circ J 2011;41:130-136)
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Introduction
Organ transplantation is the most effective and unique me-
thod of support for end-stage organ failure patients. Howev-
er, transplantation is currently limited by shortage of human 
donors. This drawback may be eliminated by xenotransplan-
tation using porcine organs, but there are several barriers to 
the transplantation of porcine organs into humans.
1-4) Hy-
peracute rejection (HAR) is the most serious complication 
when porcine organ is transplanted to human. When xeno-
antigens that exist in porcine organs bind and react with natu-
ral antibodies in human blood, the human complement sys-
tem will in turn be activated, ultimately lead to the transpl-
anted porcine organ being destroyed within minutes or ho-
urs.
5-7) Therefore, efforts to prevent HAR have concentrated 
on removing xenoreactive natural antibodies, and inhibiting 
complement activation.
5-8) Ex vivo perfusion model has been 
used to evaluate HAR in pig to human combination, because 
this allows continuous monitoring of physiologic parameters 
as well as sequential sampling of tissue and blood. Results ob-
tained from our ex vivo perfusion model may help verify the 
efficacy of treatments and provide a framework with which 
to support in vivo experiments later. 
Risk factors have been addressed frequently in many xe-
nogeneic perfusion models, such as kidney, lung and liver,
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especially they have been reported to impose the most signi-
ficant risks on xenograft function secondary to hemolysis, be-
cause severe hemolysis causes intravascular thrombi compr-
ised of fibrin and platelet, rapid reduction of coagulation fac-
tors, and results in disseminated intravascular coagulation.
9) 
However, there exist few established reports that associate 
with hemolysis in the cardiac xenotransplantation and heart 
is not similar to liver, kidney or lung. We investigated wheth-
er hemolysis may be the major risk factor of xenoperfused 
cardiac function or not. Hyperkalemia that could be induced 
by hemolysis of xenoperfused blood and myocardial cell in-
jury by HAR would fail the transplanted heart function. We 
analyzed extracellular potassium levels, and analyzed its role 
in xenoperfused cardiac function. 
In this study, we used an ex-vivo xenogeneic cardiac perfu-
sion model with porcine hearts and fresh human whole blo-
od, and then evaluated the protective effects of pre-treatments, 
such as plasmapheresis, GAS914, cobra venom factor (CVF) 
and steroid. Plasmapheresis has been used to remove anti-po-
rcine antibodies, especially IgM and IgG from human serum. 
As such, it reduces HAR secondary to natural antibodies and 
xenoantigens induction.
1)5)8)12) GAS914 is a soluble, poly-
meric form of a Gal α-1,3-Gal trisaccharide. Intravenous in-
fusion of GAS914 can successfully reduce preformed antibo-
dies in the recipient.
13-15) CVF acts as a homolog of C3 in vivo,
16) 
and administration to recipient before transplantation can 
suppress graft rejection by depleting the complement system 
in advance.
17-19) Several studies concluded that CVF admin-
istration before xenotransplantation prolonged graft surviv-
al.
20)21) To ascertain the effects of the aforementioned on xeno-
perfused porcine myocardium, we evaluated basic labora-
tory outcomes, such as complete blood cell counts (CBC), ar-
terial blood gas analysis (ABGA), and evaluated myocardial 
cell injury by measuring creatine kinase-MB (CK-MB) and 
Troponin I. In addition, we observed the histological changes 
of xenoperfused myocardium, and the effects of perfused blo-
od hemolysis and hyperkalemia on porcine cardiac function.
Materials and Methods
Animals
Outbred piglets, weighing approximately 5 kg, were used 
as cardiac donors. Piglets were chosen because they can be ea-
sily handled and their hearts are lighter than that of adult pig. 
All animal experiments were performed after receiving the 
approval of the Institutional Animal Care and Use Committee 
of the Clinical Research Institute at Seoul National University 
Hospital. National Research Council ‘Guidelines for the Care 
and Use of Laboratory Animals’ were observed (revised 1996). 
Piglet hearts were harvested as described previously.
1) Brief-
ly, the superior vena cava (SVC), inferior vena cava (IVC), aor-
ta, right innominate artery (RIA), pulmonary artery (PA), pul-
monary veins, and left azygous vein were isolated, and he-
parin (200 unit/kg of body weight) was administered throu-
gh the right atrium. The proximal RIA was cannulated with 
a 12-gauge catheter to infuse heart preservation solution and 
to connect the perfusion system for later use. The SVC, distal 
RIA and left azygous vein were ligated and the IVC was tr-
ansected. The aortic arch was cross-clamped posterior to the 
RIA by ligation with a thick string, and 20 mL/kg of body 
weight of University of Wisconsin solution was infused into 
the aortic root through the catheter. Immediate heart arrest 
was obtained and the heart was then excised. Extracted pig-
let hearts weigh about 30 g. Subsequently, the heart was con-
nected to the ex vivo xenoperfusion circuit (Fig. 1). The ische-
mic period was less than 10 minutes.
Human blood
Fresh human whole blood for perfusion was obtained from 
normal healthy male volunteers within 24 hours of the ex-
periment without pre-treatment. Use of human subjects as 
blood donors was certified by the Seoul National University 
College of Medicine and the Seoul National University Hos-
pital Institutional Review Board. Each blood unit (about 350 
mL) from one volunteer was used for a separate experiment 
after dilution with Hartmann solution. Three test groups (gr-
oup 1-3) and one control group (group 4) were formed accord-
ing to the preparation of perfused blood. Group 1 received 
normal fresh human whole blood (n=4); group 2 received hu-
man whole blood pre-treated with plasmapheresis to remove 
natural antibodies just before experiment (n=3); group 3 re-
ceived human whole blood treated with plasmapheresis, 
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Fig. 1. Diagram of the isolated, non-working heart perfusion circuit. 
Ao: aorta, RA: right atrium, RV: right ventricle, PA: pulmonary artery, 
LA: left atrium, LV: left ventricle. 
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GAS914 (Novartis Pharma Ag, 1 mg/kg), CVF (0.5 mg/kg), 
and steroid (Solumedrol 24 mg/kg, n=2); and group 4 receiv-
ed normal fresh porcine whole blood (n=2). We applied iden-
tical methods and parameters to all four groups. Plasmaph-
eresis was performed using COBE plasma filtration device 
(COBE Spectra, Lakewood, USA) and Evalflux 2A mem-
brane (Kawasumi laboratories, Tokyo, Japan) in accordance 
with the manufacturer’s instruction.
Blood perfusion to extracted hearts
Extracted hearts were connected to non-working isolated 
heart perfusion circuit with membranous oxygenator (Mini-
max, Medtronic, USA), and then blood was perfused to po-
rcine coronary artery through the innominate artery using 
roller pump (Cobe Heart-Lung machine, Cobe, USA). The 
mean aortic perfusion pressure was fixed at 80 mmHg. Each 
human blood unit was diluted with Hartmann solution before 
perfusion to maintain hemoglobin (Hb) level at 5-6 mg/mL, 
hematocrit at 15-20%. This level of Hb is sufficient to main-
tain the oxygen carrying capacity and low viscosity for artifi-
cial circuit circulation. The total volume of diluted blood was 
about 800 mL. The oxygen tension pressure was maintained 
above 150 torr. In this non-working isolated heart perfusion 
circuit, human blood flowed through the innominate artery, 
coronary arteries, right atrium, right ventricle and the main 
PA of porcine heart before re-entering the circuit again. 
Sampling and analyzing
From the beginning of blood perfusion through the porcine 
heart, we recorded the duration of heart beat until myocardial 
contraction ceased. We collected tiny pieces of myocardium 
(about 5×5×5 mm) at the apex of the left ventricle 10, 60, 120 
and 180 minutes after reperfusion, and rapidly fixed them in 
4% paraformaldehyde. Histological changes were assessed 
after routine hematoxylin and eosin staining of paraffin-em-
bedded sections. In addition, blood samples were obtained 
at defined intervals for the measurement of CBC and serum 
chemistry. They were collected before cardiac perfusion, 5 mi-
nutes intervals until 30 minutes after perfusion, every 15 mi-
nutes until 120 minutes, and then every 30 minutes until 180 
minutes. All blood samples were examined for CBC (XE-
2100D, Syxmex co. Japan), ABGA (ABL 520, Diamond Diag-
nostic, USA), cardiac enzyme (AXSYM, Abbott Lab, USA), 
serum hemoglobin (sHb, Milton Roy Spectronic 601, Phar-
macia, USA), electrolyte (Toshiba-200FR, Toshiba, Japan), 
and antibody titers (Olympus AU5421, Olympus Amerlca 
Inc., USA). 
Statistical analysis
All results are expressed as mean and standard deviation. 
We used Statistical Package for the Social Sciences (version 
10.0) statistics program for data analysis. For data comparison, 
we used the analysis of variance (ANOVA) test to compare 
heart beating time. We also used the repeated measurement 
analysis method (Repeated measures ANOVA) for changes 
in several variables of the sampled blood with time, and then 
used the Tukey test as post hoc multiple comparisons. A p< 
0.05 was considered to be a statistically significant difference.
Results
Depletion of human anti-porcine antibodies
The total elimination rates of immunoglobulin by plasma-
pheresis were 65.3% (IgM) and 77.4% (IgG) in group 2. Alth-
ough we were not aware of the precise exclusion rate of anti-
Gal specific antibodies by GAS914, the elimination rates of 
immunoglobulin in group 3 were increased to 83.7% (IgM) 
and 84.8% (IgG) respectively.
Duration of heart beating
Isolated piglet hearts started beating within 1 minute after 
perfusion in all groups. Compared to group 1, the hearts in gr-
oups 2 and 3 beat significantly longer (p=0.014). The durations 
of heart beating were 4.8±3.2 minutes (group 1), 18.0±5.0 
minutes (group 2), 15.0±5.0 minutes (group 3) and over 180 
minutes (group 4) respectively. However, there was no signi-
ficant difference between groups 2 and 3 (p>0.05).
Histological changes of porcine myocardium
Histological examination of porcine myocardium showed 
typical features of HAR, characterized by marked hemorrh-
age, congestion, interstitial edema, platelet aggregation, th-
rombi, capillary obstruction and myocardial cell destruction. 
The changes in group 1 began within 10 minutes after perfu-
sion, and the myocytes were almost morphologically destroy-
ed within 60 minutes (Fig. 2). In groups 2 and 3, myocyte 
destruction developed as in group 1, but these destructive ch-
anges were delayed and weaker compared to group 1. Particu-
larly in group 3, destructive changes were delayed more than 
the group 1 and 2, although the appearance of congestion, ch-
anges of the myocyte shape were increased as perfusion time 
elapsed (Figs. 2 and 3). In group 4, the shape of the myocyte 
was maintained relatively well, but hemorrhage increased 
gradually, similar to that in group 3. We observed that changes 
in myocytes in group 3 were similar to that observed in gr-
oup 4 (Fig. 3). 
Changes of reperfused blood
Among CBC results, leukocyte count was reduced at the be-
ginning of perfusion in all groups. There was no difference 
in hemoglobin, hematocrit levels in the xenograft groups 
(group 1, 2 and 3). Platelets, which form thrombus in organ 
rejection, was decreased at the beginning of perfusion, par-
ticularly more pronounced in group 1 (from 46.5±37.4 /L at Jun Seok Kim, et al.   133
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Fig. 2. Histologic findings of xenoperfused porcine myocardium following perfusion in group 1 (A: 10 minutes, B: 60 minutes) and group 2 
(C: 10 minutes, D: 60 minutes). Typical features of HAR were noted and myocardial destruction began within 10 minutes of perfusion (A), 
and almost all cells were destroyed within 60 minutes in group 1 (B). Morphological changes and congestion were noted in group 2 also (C 
and D), but delayed and milder than in group 1 (A and B) (H&E, Magnification ×400).
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Fig. 3. Histologic findings of xenoperfused porcine myocardium after perfusion in group 3 (A: 60 minutes, B: 180 minutes) and group 4 (C: 60 
minutes, D: 180 minutes). The degree of destruction was less and delayed in group 3, compared to groups 1 and 2 (Fig. 2B and D). The myo-
cardial cell contour was maintained relatively well in group 4, and the changes in myocytes in group 3 was similar to that in group 4 (H&E, 
Magnification ×400).134   Hyperkalemia and Hemolysis by HAR
the beginning of the perfusion to 9.5±4.9/L at 15 minutes 
later) among the xenograft groups, but there was no statisti-
cal significance (data not shown). 
Analysis of myocardial cell injury
Troponin I levels, which reflect myocardial destruction 
most distinctively, were gradually increased soon after per-
fusion commencement in all groups, particularly more pro-
nounced in group 1 (Fig. 4A), but there was no statistical sig-
nificance among the groups (p=0.25). CK-MB levels were 
gradually increased in all groups, including group 4, and early 
increase was also drastic in group 1, but not statistically signi-
ficant (Fig. 4B). However, we found the tendency of increase 
in cardiac enzymes to be the least in group 3. 
The degree of extracellular potassium and serum 
hemoglobin of perfused blood
We measured serum Hb levels to investigate the degree of 
hemolysis of perfused blood in each group. As shown in Fig. 
5A, serum Hb in group 1 demonstrated the lowest levels, and 
plasmapheresis, GAS914, CVF, and steroid (group 3) acceler-
ated hemolysis more than group 1 (p=0.018). Of interest, the 
serum Hb level in group 4 was markedly increased 30 min-
utes after perfusion without affecting heart beat (Fig. 5A). 
Potassium levels that reflect myocardial cell injury and 
perfused blood cells were increased sharply at the beginning 
of perfusion in all xenograft groups (group 1, 2 and 3), but 
there was no difference between these xenograft groups. The 
potassium level of group 4 was increased only mildly at the end 
of reperfusion, the degree of increase was significantly dif-
ferent from the other xenograft groups (p=0.043) (Fig. 5B).
Discussion
We measured the levels of cardiac enzymes, including CK-
MB and Troponin I, to evaluate the extent of myocardial cell 
injury. There are several reports about plasmapheresis, GAS 
914, CVF or other agent on myocardial function preserva-
tion against HAR,
1)8)12)28) but there are few studies that analyz-
ed cardiac enzyme to determine the extent of myocardial injury.
Our results of heart beating time, morphologic changes and 
cardiac enzyme levels reflect that the use of plasmapheresis, 
GAS914, CVF, and steroid has a protective effect on xenoper-
fused piglet heart, particularly in the earlier period of xenoper-
Fig. 4. The levels of Troponin I (A) and CK-MB (B). They increased gradually in all groups, including group 4, especially after perfusion be-
gan in group 1, and were lowest in group 3.
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fusion. These treatments delayed and weakened xenoperfused 
myocardial injury. Although individual application of plas-
mapheresis, GAS914, CVF and steroid may have exerted pro-
tective effect on the xenotransplanted heart against HAR, ap-
plying a combination of these treatments may have exerted 
more protective effects than would have conferred by mono-
therapy with one treatment. Depletion of natural antibodies 
by various methods has resulted in prolonged survival of xe-
nografted organs in the pig-to-primate combination.
6)22) In our 
previous experiment,
1) the duration of porcine heart beat in 
pig-to-dog heterotopic transplantation model without plas-
mapheresis was on average 5 minutes, which was prolonged 
to an average of 90 minutes after plasmapheresis. In another 
study,
23) survival of the xenotransplanted heart in which IgM 
and IgG were respectively reduced to 95.9%, 80.2% by plas-
mapheresis, was prolonged to 107±47 minutes, copared to 
hearts without plasmapheresis, which failed in 9±5 minutes. 
The survival time of the transplanted heart extended to 240± 
141 minutes from 3 minutes when the natural antibodies were 
removed by plasmapheresis and immunoadsorption simul-
taneously.
24) In this report, IgM and IgG were reduced to 
93.9%, and 85.5% respectively.
24) In our study, IgM and IgG 
were reduced respectively to 65.3%, 77.4% by plasmaphere-
sis. These relatively low elimination rate of immunoglobulin 
is the limitation of ex vivo experiment. The total titer of nat-
ural antibodies were eliminated to a higher extent in group 3 
treated with GAS914. Although we did not know the amount 
of anti-Gal specific antibody removed by GAS914 precisely, 
qw presume the effect of GAS914 on the antibody removal be-
cause the total elimination rates of IgM and IgG were incre-
ased from 65.3% and 77.4% in group 2 to 83.7% and 84.8% 
in group 3, respectively. 
Hemolysis is considered a sign of graft vs. host rejection. 
However, the mechanisms of hemolysis in organ xenotrans-
plantation have not yet been fully elucidated.
9) Two factors 
may be implicated in hemolysis in our study. First, is mechan-
ical hemolysis induced by the circuit itself, and the second is 
related to immunologic reactions. When we think the circuit 
conditions were identical to all groups, immunologic reaction 
can be considered a main cause of hemolysis.
25) Endothelial 
damage and dysfunction of the xenoperfused organ may lead 
to deposition of fibrin and formation of platelet thrombi.
25) 
This fibrin might have directly damage the perfused erythro-
cytes, resulting in intravascular hemolysis.
9) We had expected 
that the extent of hemolysis would be lowest in the combined 
treatment group (group 3) among the xenograft groups be-
fore commencing this study. However, the results showed that 
more pretreatment administered, the more hemolysis occurr-
ed. Therefore, we inferred that procedures used in group 3 mi-
ght have rendered the perfused erythrocyte membrane sus-
ceptible to hemolysis by the circuit, or by immunologic reac-
tion. A report discussed that the major complication of pla-
smapheresis using membrane filtration was hemolysis.
26) In 
another study, CVF was proven to be a proteolytic enzyme, th-
rombin-like substance and exerted hemorrhagic inclination.
27) 
Thus, plasmapheresis and CVF could be used to suppress myo-
cardial injury against HAR, but it is necessary to determine 
ways of minimizing hemolysis before applying these agents. 
We pondered if hemolysis impose a major risk on xenoper-
fused cardiac function, similar to that in kidney, liver and lung 
functions. However, our results showed that hemolysis exert-
ed less impact on cardiac function than on other organs. Be-
cause the hearts in group 4 beat strongly for over 3 hours, des-
pite the occurrence of hemolysis after 30 minutes, and the he-
arts in group 3 beat longer than that in group 1, even though 
hemolysis in group 3 was much more severe than in group 1 
(Fig. 5A). 
The most important risk factor determining cardiac func-
tion was the potassium level, rather than hemolysis in our stu-
dy. Potassium levels sharply upsurged to 10-14 mmol/L in the 
early perfusion period in all xenograft groups (Fig. 5B). This 
increased extracellular potassium disturbed heart beat in the 
early perfusion period. Although the levels of released cardi-
ac enzymes in group 3 were similar or even lower than that 
in group 4, and although the morphological changes of the 
myocardium in group 3 was similar to that in group 4, the 
duration of transplanted heart beat in group 3 was much sh-
orter than that in group 4. This remarkable difference in heart-
beat resulted from difference in extracellular potassium lev-
els (Fig. 5B). Increased extracellular potassium levels in the 
early perfusion period were regarded as a side effect of hemo-
lyzed perfused RBC or myocyte destruction. However, the in-
creased potassium levels were not correlated with the extent 
of hemolysis in all groups (Fig. 5A). The main source of in-
creased potassium is likely from injured piglet myocytes, 
rather than hemolyzed RBC. Thus, potassium level could be 
a parameter demonstrating myocardial cell injury in ex vivo 
cardiac perfusion models. 
In this study, we investigated the major risk factors of xeno-
perfused cardiac function. Our data, including duration of 
heart beat, histological findings, and cardiac enzyme levels 
show that therapy with plasmapheresis, GAS914, CVF and 
steroid may reduce and delay the destruction of xenoperfused 
porcine myocardium by HAR. However, these therapy did 
not ameliorate myocardial function because of increased ex-
tracellular potassium caused by HAR. 
In conclusion, one major risk factor that impairs graft func-
tion in xenoperfused heart was the high level of extracellular 
potassium, and not hemolysis, in our ex vivo study. 
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